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ABSTRACT
Background
The epidermal growth factor receptor (EGFR) plays a critical role in the control of cellular
proliferation, differentiation, and survival. Abnormalities in EGF-EGFR signaling, such as
mutations that render the EGFR hyperactive or cause overexpression of the wild-type receptor,
have been found in a broad range of cancers, including carcinomas of the lung, breast, and
colon. EGFR inhibitors such as gefitinib have proven successful in the treatment of certain
cancers, particularly non-small cell lung cancers (NSCLCs) harboring activating mutations within
the EGFR gene, but the molecular mechanisms leading to tumor regression remain unknown.
Therefore, we wished to delineate these mechanisms.
Methods and Findings
We performed biochemical and genetic studies to investigate the mechanisms by which
inhibitors of EGFR tyrosine kinase activity, such as gefitinib, inhibit the growth of human
NSCLCs. We found that gefitinib triggered intrinsic (also called ‘‘mitochondrial’’) apoptosis
signaling, involving the activation of BAX and mitochondrial release of cytochrome c, ultimately
unleashing the caspase cascade. Gefitinib caused a rapid increase in the level of the
proapoptotic BH3-only protein BIM (also called BCL2-like 11) through both transcriptional and
post-translational mechanisms. Experiments with pharmacological inhibitors indicated that
blockade of MEK–ERK1/2 (mitogen-activated protein kinase kinase–extracellular signal-
regulated protein kinase 1/2) signaling, but not blockade of PI3K (phosphatidylinositol 3-
kinase), JNK (c-Jun N-terminal kinase or mitogen-activated protein kinase 8), or AKT (protein
kinase B), was critical for BIM activation. Using RNA interference, we demonstrated that BIM is
essential for gefitinib-induced killing of NSCLC cells. Moreover, we found that gefitinib-induced
apoptosis is enhanced by addition of the BH3 mimetic ABT-737.
Conclusions
Inhibitors of the EGFR tyrosine kinase have proven useful in the therapy of certain cancers, in
particular NSCLCs possessing activating mutations in the EGFR kinase domain, but the
mechanisms of tumor cell killing are still unclear. In this paper, we demonstrate that activation
of the proapoptotic BH3-only protein BIM is essential for tumor cell killing and that shutdown
of the EGFR–MEK–ERK signaling cascade is critical for BIM activation. Moreover, we
demonstrate that addition of a BH3 mimetic significantly enhances killing of NSCLC cells by
the EGFR tyrosine kinase inhibitor gefitinib. It appears likely that this approach represents a
paradigm shared by many, and perhaps all, oncogenic tyrosine kinases and suggests a
powerful new strategy for cancer therapy.
The Editors’ Summary of this article follows the references.
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PLoS MEDICINEIntroduction
The epidermal growth factor receptor (EGFR) is a type I
surface-bound receptor tyrosine kinase of the ErbB receptor
family. Its activation by physiological ligands (e.g., EGF)
causes EGFR homodimerization or heterodimerization of
EGFR with other members of the ErbB family, resulting in
activation of diverse signaling molecules such as extracellular
signal-regulated protein kinase 1/2 (ERK1/2), protein kinase B
(AKT), and signal transducer and activator of transcription
proteins (STATs), which regulate cellular proliferation,
survival, differentiation, and migration (reviewed in [1]).
EGFR function is commonly dysregulated in a range of solid
cancers (e.g., breast, lung, ovarian, bladder, brain, and colon)
due to either gene ampliﬁcation, mutations (resulting in a
constitutively active EGFR), or abnormally increased ligand
production (reviewed in [1]). Moreover, enforced expression
of mutant EGFR in transgenic mice promoted development
of lung carcinomas [2,3]. These observations prompted the
development of EGFR inhibitory drugs for cancer therapy.
The EGFR tyrosine kinase inhibitors geﬁtinib (Iressa, Astra-
Zeneca) and erlotinib (Tarceva, Genentech) as well as the
monoclonal antibody cetuximab (Erbitux, Merck), which
blocks ligand binding, cause substantial regression of a small
proportion of non-small cell lung cancers (NSCLCs), partic-
ularly those with EGFR mutations that give rise to hyperactive
kinases [1,4–6]. Signaling from mutant but not wild-type (WT)
EGFR was shown to activate anti-apoptotic pathways, and
small interfering RNA-mediated down-regulation of mutant
EGFR resulted in the death of these cells [7], but the
mechanisms for tumor cell killing were not examined.
Mammals have two distinct but ultimately converging
apoptosis signaling pathways [8], the extrinsic pathway, which
is activated by ‘‘death receptors,’’ and the intrinsic (also called
‘‘mitochondrial’’ or ‘‘BCL-2-regulated’’) pathway [9]. The
BCL-2 family of proteins regulate the intrinsic apoptosis
signaling pathway, and according to their structure and
function they can be divided into three groups. The BAX- and
BAK-like proteins, which share three regions of homology
(BCL-2-homology [BH] domains), are proapoptotic and
perturb the mitochondrial membrane potential when acti-
vated, resulting in release of cytochrome c, activation of the
caspase cascade, and cellular destruction [10]. To prevent cell
death, BAX and BAK are bound and inhibited by the
antiapoptotic members of the BCL-2 family (BCL-2, BCL-
xL, BCL-w, MCL-1, and A1), which share up to four BH
regions [10]. The third subgroup, the BH3-only proteins
(BAD, BID, BIK [also called BLK or NBK], HRK [also called
DP5], BIM [also called BOD], NOXA, PUMA [also called
BBC3], and BMF), share with each other and the remainder of
the BCL-2 family only the 9- to 16-amino acid BH3 domain.
The BH3-only proteins initiate apoptosis signaling by binding
and antagonizing the prosurvival BCL-2 family members,
thereby causing activation of BAX and BAK [11]. BH3-only
proteins can be regulated by a range of transcriptional and
post-translational mechanisms [12], and experiments with
gene-targeted mice have shown that different members of
this subgroup are required for the execution of different
death stimuli. For example, PUMA and to a lesser extent
NOXA are critical for DNA damage-induced apoptosis [13–
15], whereas BIM is essential for hematopoietic cell homeo-
stasis and cytokine deprivation-induced apoptosis [16].
Here, we studied the molecular mechanisms through which
certain NSCLC tumor cell lines expressing mutant but not
wild-type (WT) EGFR undergo apoptosis after treatment with
the EGFR inhibitor geﬁtinib.
Methods
Cell Lines, Expression Vectors, and Cell Transfection
The NSCLC cell lines NCI-H358, NCI-441, NCI-H1650, and
NCI-H1975 were all obtained from ATCC. NCI-H3255 cells
were obtained from Drs. Bruce Johnson and Kreshnik
Zejnullahu (Dana Faber, Boston). (NCI is left out from the
nomenclature hereafter). HCC827 cells were a kind gift of Dr.
Dan Costa (Department of Medicine, Harvard Medical
School, Boston, MA). H358 and H441 cells express WT EGFR,
whereas H1650 and HCC827 cells harbor an exon 19
mutation (DelE746A750) and H3255 cells possess a single
amino acid substitution mutation (L858R) in the EGFR gene.
H1975 cells harbor two mutations (L858R and T790M) in the
EGFR gene. All cells were maintained in RPMI-1640 medium
supplemented with 10% heat-inactivated fetal calf serum
(FCS, JRH Biosciences, Lenexa, Kansas). The caspase inhibitor
QVD-OPH (MP Biomedicals, Aurora, Ohio) was used at 25 lM
and added to cells 30 min prior to treatment with geﬁtinib.
Kinase inhibitors UO126, PD98059 (CST, Beverley, MA), SP6,
LY294002, AKT inhibitor Akti1/2 (Merck), ABT-737, geﬁtinib
(AstraZeneca), erlotinib, and cetuximab (gifts from Dr.
Thomas Valerius, University of Schleswig-Holstein, Germany)
were dissolved in DMSO and used as indicated. The anti-BIM
short hairpin RNA construct, cloned into pSUPER with the
neomycin-resistant gene, has been described previously [17].
Transfection with Fugene (Roche, Indianapolis, IN) was
performed according to the manufacturer’s instructions and
vector-transfected clones were selected with 1 mg/ml Genet-
icin (Gibco BRL, Grand Island, NY). Cell lines were single cell-
cloned by limiting dilution.
Western Blotting
Protein samples were separated by SDS-PAGE and then
electroblotted onto a PVDF membrane (Hybond P, Amer-
sham Biosciences). Antibodies against BCL-w (clone 13F9;
Alexis), BCL-xL (BD/Pharmingen), BIM (clone 3C5, Alexis; or
polyclonal antibodies from Stressgen), BAD (Stressgen),
phospho-BAD (phosphorylated at Ser112), phospho-BAD
(Ser136), phospho-ERK1/2 (Thr202/Tyr204), total ERK1/2,
phospho-AKT (193H12, Ser473), total AKT, phospho-EGFR
(Tyr1068), total EGFR (all from CST), BAX (Upstate), human
BMF (polyclonal antibody from Alexis), HSP70 (N6; gift from
Dr. R Anderson, Peter MacCallum Cancer Institute, Mel-
bourne, Australia), MCL-1 (Dako), PARP (Alexis), PUMA (NT,
Pro-Sci), and b-actin (Sigma) were used as indicated by the
manufacturers. Detection was performed with horseradish
peroxidase-conjugated secondary antibodies (speciﬁc to rat,
mouse, hamster, or rabbit IgG) and enhanced chemilumines-
cence (Amersham Biosciences).
Two-Dimensional Gel Electrophoresis
Two-dimensional protein gel electrophoresis was per-
formed using the IPGphor isoelectric focusing system
(Amersham Biosciences). BIM was isolated from cell lysates
by immunoafﬁnity chromatography using mAb 3C5 (Alexis).
Samples were then loaded onto IPG gels, rehydrated at 20 8C
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After equilibration with SDS-PAGE buffer for 15 min at room
temperature, the IPG gel was subjected to SDS-PAGE.
Transfer, immunoblotting and visualization were performed
as described above.
Reverse Transcriptase Polymerase Chain Reaction
TotalRNAwas extractedusingtheMicro-to-MidiTotalRNA
Extraction Kit (Invitrogen), and total RNA subjected to reverse
transcription. For semiquantitative analysis, cDNA was sub-
jected to PCR, using primers for BIM, with samples removed
after a given number of cycles. Primers for BIM were used as
previously described [18]. b-actin was used as a control for the
quality and abundance of RNA. For quantitative PCR analysis
of BIM and PUMA expression, TaqMan probes were used in
conjunction with an ABI-PRISM 7900 thermal cycler (Applied
Biosystems) according to the manufacturer’s instructions. b2
microglobulin was used as a control for the quality and
abundance of RNA. Fold induction of BIM and PUMA was
calculated by comparing Ct values of treated and untreated
samples after ﬁrst correcting for RNA abundance.
Cell Death Assays
Cell death was assessed following release of the cells from
the culture dish through trypsinization. Cell death was
assessed by ﬂow cytometric analysis in a FACScan (Becton
Dickinson), either by staining with propidium iodide (PI) plus
Annexin V-FITC or by assessing the extent of DNA
fragmentation as detailed previously [19]. The latter technique
was also performed to assess changes in cell cycle distribution.
Assays for BAX Activation
Activation status of BAX was assessed using the activation-
speciﬁc mAb for BAX, followed by ﬂow cytometric analysis as
detailed previously [20]. Alternatively, BAX activation was
assessed by following its redistribution from the cytosolic to
the membrane fraction by subcellular fractionation using
digitonin lysis followed by SDS-PAGE and Western blotting,
as detailed previously [20]. Membranes were also probed to
determine whether cytochrome c had been released from the
mitochondria (redistribution from the membrane to the
cytosolic fraction) and for BAK (membrane-resident) as well
as HSP70 (cytosol-resident) as controls for the quality of
subcellular fractionation and protein loading.
Results
Varying Sensitivities of NSCLC Cell Lines to Gefitinib-
Induced Apoptosis
The NSCLC cell lines H358 (WT EGFR), H1650, HCC827
(Del E746A750 deletions) and H3255 (L858R mutation)
[5,7,21,22] were chosen for initial studies on the effects of
geﬁtinib. Geﬁtinib potently inhibited the activation of ERK1/2
in all three cell lines expressing mutant EGFR, as judged by its
dephosphorylation, whereas the H358 cells expressing WT
EGFR were unaffected, as previously reported (Figure 1A)
[5,7,21,22]. Extensive apoptosis was observed only in H3255
and HCC827 cells (Figure 1B). H1650 cells displayed only a low
level of apoptosis and H358 cells were refractory. In addition,
we also examined H1975 cells, which were originally reported
as geﬁtinib sensitive [7]. However, we found that geﬁtinib
treatment of these cells did not result in dephosphorylation of
ERK1/2 (Figure 1A) or substantial apoptosis (Figure 1B),
presumably due to the presence of the additional (T790M)
mutation, known to reduce the kinase activity of EGFR,
rendering it effectively wild type [23]. Next, we assessed the
mechanism of cell death in the highly sensitive H3255 cells.
Mechanisms of Gefitinib-Induced Apoptosis
Apoptosis after treatment of H3255 cells with geﬁtinib
featured PARP cleavage and phosphatidylserine exposure (as
detected by staining with FITC-coupled Annexin V), was
caspase dependent and involved activation of BAX and
mitochondrial release of cytochrome c (Figure S1). BAX
activation was revealed both by ﬂow cytometric analysis using
antibodies that recognize activated BAX and by subcellular
fractionation, which showed that a substantial proportion of
Figure 1. Effect of Gefitinib on NSCLC Cells Expressing WT or Mutant
EGFR
NSCLC cells expressing WT (H358) or mutant (HCC827, H1975, H1650,
H3255) EGFR were treated with varying concentrations of gefitinib for 24
h (A) or 72 h (B). Cells were then either assessed for the phosphorylation
status of ERK (A) or cell death (B). Western blotting (A) was performed to
determine the phosphorylation status of ERK1/2 before and after
treatment with gefitinib. An actin loading control is also shown. Cell
death was assessed by Annexin V-FITC plus PI staining (B). Results
represent mean 6 standard error of the mean (SEM) of at least three
experiments. NT, no treatment.
doi:10.1371/journal.pmed.0040316.g001
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BIM in Gefitinib-Induced ApoptosisBAX redistributed from the cytosol to the mitochondrial
fraction after treatment with geﬁtinib (Figure S1D and S1E).
BAX and BAK are activated when prosurvival BCL-2 family
members are antagonized by the proapoptotic BH3-only
proteins [11]. In all three mutant EGFR-expressing cell lines,
geﬁtinib caused a signiﬁcant induction of BIM in a time- and
dose-dependent manner (Figures 2A, S2, and S3). BIM has a
number of isoforms, the major ones designated BIMEL (extra
long), BIML (long), and BIMS (short), which are generated
through alternative splicing and therefore differ in molecular
weight [24]. We routinely observed BIMEL and BIML isoforms
in our geﬁtinib-treated cells, with BIMEL the most highly
expressed (Figure 2A). In accordance with the differential
sensitivity of the cell lines to geﬁtinib-induced apoptosis, BIM
induction was more prominent in H3255 cells compared to
the HCC827 and H1650 cells (Figure 2A). The expression of
other BH3-only proteins (BMF, BAD, and PUMA) and the
prosurvival BCL-2 family members BCL-w, BCL-xL, and MCL-
1 did not change signiﬁcantly in either the H3255 or H1650
cells after treatment with geﬁtinib (Figure 2B). Notably, BIM
was not strongly induced in two NSCLC cell lines expressing
WT EGFR or in the H1975 cells expressing the L858R and
T790M mutant EGFR (Figure S4). Therefore, the extent of
BIM induction after geﬁtinib treatment correlated directly
with the extent of apoptosis induced in the NSCLC cells.
BIM Is Essential for Gefitinib-Induced Apoptosis of NSCLC
Cells
To examine the role of BIM in geﬁtinib-induced cell killing,
we generated multiple subclones of H3255 cells stably
expressing a BIM RNA interference (RNAi) construct. In
these transfectants BIM expression was reduced, even after
treatment with geﬁtinib (Figure 3A and 3B). BIM knockdown
protected H3255 cells potently against geﬁtinib over a range
of concentrations, and the level of protection correlated with
the extent of BIM reduction in these subclones (Figure 3C
and 3D). The BIM RNAi transfectants still responded to
geﬁtinib, as judged by its ability to elicit dephosphorylation of
EGFR as well as its downstream targets ERK1/2 and to induce
G1 cell cycle arrest (Figure 3B and unpublished data).
Gefitinib Causes Increased BIM Transcription as well as
Post-translational Modifications in BIM
The proapoptotic activity of BIM can be regulated by a
range of transcriptional and post-translational mechanisms
[12]. Semiquantitative reverse transcriptase PCR and quanti-
tative PCR analyses demonstrated that geﬁtinib induced a
substantial (;3-fold) increase in BIM mRNA in H3255 cells
and to a lesser extent in H1650 cells (Figures S5A and S5B).
The induction of BIM was speciﬁc, as expression of other
BH3-only genes was not elevated and the levels of PUMA
mRNA actually fell after geﬁtinib treatment (Figure S5C).
The electrophoretic mobility of BIMEL changed rapidly
(within 15–60 min) after geﬁtinib treatment of H3255 cells,
coinciding with loss of ERK1/2 activity (Figure S6A). BIMEL
has multiple phosphorylation sites and its proapoptotic
activity can be down-regulated through ERK-mediated
phosphorylation, which targets it for ubiquitination and
proteasomal degradation [12,25,26]. Treatment of cell lysates
with k phosphatase showed that BIMEL and BIML are
phosphorylated in healthy but not in geﬁtinib-treated cells
(Figure 2C). Two-dimensional gel electrophoresis and West-
ern blotting demonstrated that BIMEL and BIML immuno-
precipitated from geﬁtinib-treated H3255 cells had less
negative charge than BIM from untreated cells, conﬁrming
the accumulation of dephosphorylated forms of BIM (Figure
2D). The levels of phosphorylated BAD (Ser136 but not
Ser112) dropped after geﬁtinib treatment (Figure S6B), likely
as a consequence of shutdown of the AKT and/or ERK1/2
pathways, which are known to promote phosphorylation of
BAD and thereby inhibit its proapoptotic activity [27].
However, signiﬁcant BAD dephosphorylation occurred only
when apoptosis was already underway, perhaps indicating
that it is a consequence rather than an initiator of cell death.
Unfortunately, our attempts to decrease BAD expression in
Figure 2. Induction and Dephosphorylation of BIM after Gefitinib
Treatment in NSCLC Cells Expressing Mutant EGFR
(A) In the blot on the left, H1650 cells were left untreated (NT) or treated
with 1 lM gefitinib (G) for 24, 48, or 72 h and the cells harvested, lysed,
and assessed by Western blotting for the expression of BIM. HCC827 or
H3255 cells (center and right, respectively) were treated for 16 h with a
range of concentrations of gefitinib (10–0.08 lM) and the expression of
BIM analyzed as above. Actin is shown as a loading control.
(B) H1650 or H3255 cells were treated as in (A) and then BH3-only
proteins, prosurvival BCL-2 family members, or b-actin (loading control)
assessed by Western blotting.
(C) H3255 cells were left untreated (NT) or treated for 16 h with 1 lM
gefitinib (Gef) and the cells harvested and lysed. Portions of the samples
were then treated with k-phosphatase (þ) or left untreated ( ) and then
assessed by Western blotting for BIM (labeled BimEL and BimL).
(D) H3255 cells were left untreated or treated for 16 h with 1 lM gefitinib
and the cells harvested and lysed. BIM (labeled BimEL and BimL) was
isolated by immunoaffinity chromatography and subjected to two-
dimensional gel SDS-PAGE followed by Western blotting for BIM.
doi:10.1371/journal.pmed.0040316.g002
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BIM in Gefitinib-Induced Apoptosisthe H3225 cells by RNAi have so far failed, so the importance
of BAD in geﬁtinib-induced death remains to be determined.
Signal Transduction Pathways Leading to BIM Activation
That Are Affected by Gefitinib
To identify the critical pathways responsible for BIM
transcriptional induction and BIM dephosphorylation after
geﬁtinib treatment, we employed a range of speciﬁc inhibitors
to block MEK (UO126 or PD98059), PI3K (LY294002), or JNK
(SP6). These studies revealed that MEK inhibition alone was
sufﬁcient to induce rapid (within 1 h) dephosphorylation of
BIMEL and BIML, whereas PI3K and JNK inhibitors had no
effect (Figure 4A). Although the extent of BIM induction after
16 h of treatment correlated with the potency of MEK
inhibition (UO126 is a more potent inhibitor than PD98059
[28]), it was not able to cause BIM up-regulation to the extent
seen with geﬁtinib (Figure 4B). Similar results were also
observed in H1650 and HCC827 cells (Figure 4C) in which
MEK inhibition caused an increase in the expression and
dephosphorylation of BIMEL but to a lesser extent than that
induced with geﬁtinib. Therefore, although MEK–ERK1/2
inhibition appears important for BIM dephosphorylation
and accumulation, other signaling pathways are involved to
achieve maximal BIM induction. The obvious candidate would
be the PI3K–AKT pathway. Surprisingly, the well-established
PI3K inhibitor LY294002 caused only incomplete AKT
dephosphorylation in the H3255 cells, in contrast to geﬁtinib,
which achieved almost complete AKT dephosphorylation
(Figure 4A). Therefore, to explore the importance of the
PI3K/AKT pathway further, we employed a number of addi-
tional inhibitors of PI3K (Wortmannin), mTor (rapamycin), or
AKT (Akti1/2) [29]. Although Wortmannin and the AKT
inhibitor induced complete AKT dephosphorylation, they
did not result in BIM accumulation (Figure 4D). This indicates
that effects of geﬁtinib on the PI3K–AKT pathway may not be
required for full BIM induction in NSCLC cells, but it remains
possible that AKT triggers other antiapoptotic pathways (e.g.,
BAD inactivation) in these cells. This suggestion is supported
by the observation that although BIM levels did not rise
substantially upon treatment with either PI3K or AKT
inhibitors, both induced apoptosis (unpublished data).
EGFR Inhibitors Other than Gefitinib also Cause BIM
Induction in NSCLC Cell Lines
Since geﬁtinib caused activation of BIM in NSCLC cells
harboring EGFR mutations, we investigated whether other
EGFR inhibitors had similar effects. Addition of cetuximab (a
monoclonal antibody inhibitor of EGFR) resulted in the
induction of BIM, although to a lower extent compared to
treatment with geﬁtinib. This correlated with lower levels of
inactivation (dephosphorylation) of EGFR and ERK1/2
(Figure 4E) and also less cell killing (Figure 4F), in line with
recent reports [30]. In contrast, a second EGFR tyrosine
kinase inhibitor, erlotinib, achieved levels of inactivation of
EGFR, AKT, and ERK similar to geﬁtinib and resulted in
comparable levels of BIM induction, BIM dephosphorylation
(Figure 4E), and cell death (unpublished data). Combining the
MEK inhibitor UO126 with cetuximab resulted in increased
levels of BIM (Figure 4E) and cell death (Figure 4F) compared
to treatment with cetuximab alone, illustrating the impor-
tance of inhibiting the ERK1/2 signaling pathway for efﬁcient
BIM accumulation. However, it should be noted that geﬁtinib
reproducibly induced more cell death than did the combi-
nation of cetuximab and UO126 (Figure 4F), indicating that
other MEK-ERK–independent signaling pathways also con-
tribute to cell death after geﬁtinib treatment.
EGFR Inhibitors and the BH3-Mimetic ABT-737 Synergize
in the Killing of NSCLC Cell Lines
On their own, EGFR inhibitors such as geﬁtinib or erlotinib
are unlikely to provide cures in the majority of NSCLC
patients, even those harboring mutant EGFR. Therefore, we
explored how to augment the effects of these drugs. BH3
mimetics such as ABT-737 bind with high afﬁnity to BCL-2,
BCL-xL, and BCL-w, and kill certain tumor cells when used
alone or in combination with chemotherapeutic drugs or c-
irradiation [31]. We found that ABT-737 substantially
enhanced geﬁtinib-induced apoptosis in H3255 cells and
even in the relatively insensitive H1650 cells (Figure 5).
Figure 3. BIM Knockdown by RNAi Protects H3255 Cells against
Gefitinib-Induced Killing
(A) Western blot analysis documents the level of BIM expression in
parental and BIM RNAi knockdown subclones of H3255 cells. Probing
with an antibody to total ERK (T ERK) was used as a loading control.
(B and C) Parental and BIM RNAi knockdown subclone #21 of H3255 cells
were left untreated (NT) or treated for 18 h with gefitinib (1–0.04 lM)
prior to cell lysis and Western blotting (B) or assessment of cell death (C).
Blots (B) were probed with antibodies specific to phosphorylated EGFR
(pEGFR), phosphorylated ERK (pERK), BIM or b-actin (loading control). Cell
viability (C) was determined by staining with Annexin V-FITC plus PI,
followed by flow cytometric analysis.
(D) Parental and BIM RNAi knockdown subclones (#21, #27, and #42) of
H3255 cells were treated for 24 h with DMSO (vehicle control; NT) or 1
lM gefitinib and cell death assessed as above. Data represent means 6
SEM of three experiments.
doi:10.1371/journal.pmed.0040316.g003
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BIM in Gefitinib-Induced ApoptosisFurthermore, ABT-737 modestly enhanced the geﬁtinib-
induced apoptosis of the H1975 cells. These results therefore
demonstrate that EGFR inhibitors and the BH3 mimetic
ABT-737 synergize in the killing of NSCLC cell lines.
Discussion
In this paper, we demonstrate that activation of the
proapoptotic BH3-only protein BIM is essential for tumor
cell killing and that shutdown of the EGFR–MEK–ERK signal-
ing cascade is critical for BIM activation. Moreover, we
demonstrate that addition of a BH3 mimetic signiﬁcantly
enhances killing of NSCLC cells by the EGFR tyrosine kinase
inhibitor geﬁtinib.
Recentdata havehighlightedthefactthat inhibitors directed
to criticalreceptors,kinases,and enzymesthatare dysregulated
during tumorigenesis present unique and powerful targets for
cancer therapy. A prime example is the BCR-ABL fusion
product, which results from the reciprocal t(9;22)(q34;q22)
chromosomal translocation (Philadelphia [Ph
1] chromosome),
essential for development and sustained growth of chronic
myelogenous leukemia and Ph
1-positive (Ph
1þ) acute lympho-
Figure 4. Role of Shutdown of the MEK, JNK, PI3K, and AKT Signaling Pathways in BIM Dephosphorylation and Accumulation
(A and B) H3255 cells were treated with UO126 (UO, 20 lM), PD98059 (PD, 20 lM), LY294002 (LY, 25 lM), Sp6 (20 lM), or gefitinib (Gef, 1 lM) for 1 h (A)
or 16 h (B) and then harvested, lysed, and assessed by Western blotting. Blots were probed for phosphorylated AKT (pAKT), total AKT (T AKT),
phosphorylated ERK (pERK), total ERK (T ERK) and BIM.
(C) H1650 and HCC827 cells were treated for 24 h with either UO126 (20 lM) or gefitinib (1 lM) and then harvested, lysed, and assessed by Western
blotting for the levels of BIM, phosphorylated ERK (pERK), and total ERK (T ERK).
(D) H3255 cells were treated for 16 h with gefitinib (Gef, 1 lM), LY294002 (LY, 25 lM), Wortmannin (Wm, 1 lM), AKT inhibitor (AI, 20 lM), or rapamycin
(Ra, 100 ng/ml) and then harvested, lysed, and assessed by Western blotting as in (A).
(E) H3255 cells were treated for 16 h with various combinations of cetuximab (C, 10 lg/ml), UO126 (20 lM), erlotinib (E, 1 lM), or gefitinib (Gef, 1 lM)
and then harvested, lysed, and assessed by Western blotting as in (A).
(F) H3255 cells were treated for 48 h with various combinations of cetuximab (C, 10 lg/ml), UO126 (20 lM), or gefitinib (Gef, 1 lM) and then cell death
assessed as previously. Data represent means 6 SEM of at least three experiments.
doi:10.1371/journal.pmed.0040316.g004
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BIM in Gefitinib-Induced Apoptosisblastic leukemias [32]. Inhibition of BCR-ABL using the speciﬁc
kinase inhibitor imatinib (Gleevec) results in cell death and
tumor regression [33]. Recently, we showed that the cell death
pathway evoked iscriticallydependent on BIMwithsupporting
roles for BAD and BMF [34].
Here, we show that inhibition of the mutant EGFR found in
certain NSCLC cells triggers cell death through a similar
mechanism. We also show that three NSCLC cell lines
expressing activating mutants of EGFR, but not cell lines
expressing wild-type EGFR or mutant EGFR with wild-type
signaling potential (H1975), are sensitive to apoptosis
induced by the EGFR inhibitor geﬁtinib. Of the three cell
lines with the hyperactive EGFR, H1650 cells were much less
sensitive than the H3255 and HCC827 cells, and apparently
much less sensitive to EGFR inhibition than previously
reported, where 90% cell death was induced after small
interfering RNA knockdown of the mutant EGFR [7]. Two
independent vials of H1650 (obtained from ATCC) displayed
the same sensitivity to geﬁtinib. For this reason we can only
assume that genetic drift has occurred from the original cells
reported in the earlier work. Notably, similar geﬁtinib
resistance of this cell line has been reported independently
(Costa and Kobayashi, personal communication). Potentially,
protection from geﬁtinib-induced apoptosis in H1650 cells
relates to its higher level of pAKT and/or pERK1/2 (unpub-
lished data), since an inability of geﬁtinib to block AKT and/
or ERK1/2 activation has previously been linked to apoptosis
resistance in NSCLC cells [21,35].
Death of the sensitive H3255 cells was associated with the
subcellular redistribution and activation of BAX, and was
caspase dependent as judged by the clear PARP cleavage and
inhibition of apoptosis by the caspase inhibitor QVD-OPH.
Activation of BAX was more readily apparent in the presence
of QVD-OPH, presumably due to the inhibition of cell
destruction and consequent BAX degradation. This result is
consistent with the view that BAX is activated through a
caspase-independent pathway and is situated upstream of
caspase activation in the cell death pathway.
Western blot analysis revealed that geﬁtinib consistently
induced BIM in all three NSCLC lines expressing mutant
EGFR. The level of BIM induction was higher in the H3255
and HCC827 cells, in accordance with their greater sensitivity
to apoptosis than the H1650 cells. BIM induction preceded
apoptosis, and RNAi-mediated BIM knockdown protected
H3255 cells potently from geﬁtinib with the level of
protection correlated with the extent of BIM reduction in
various subclones. These results demonstrate that BIM is
essential for the initiation of geﬁtinib-induced apoptosis in
these cells. Similar dependence on BIM for geﬁtinib-induced
apoptosis of HCC827 cells has been observed independently
(Costa and Kobayashi, personal communication).
The induction of BIM was a consequence of both tran-
scriptional induction and post-translational modiﬁcation.
Post-translational regulation of BIM after geﬁtinib treatment
involved rapid dephosphorylation and was a result of ERK1/2
inhibition, downstream of MEK shutdown. ERK1/2 kinases are
known to phosphorylate BIM and regulate its turnover in
cells by targeting it for ubiquitination and subsequent
proteasomal degradation [26,36,37]. Therefore, inhibition of
ERK1/2 provides a mechanism through which EGFR blockade
by geﬁtinib elicits BIM accumulation. Although geﬁtinib-
induced dephosphorylation of BIM could be mimicked by
treatment with MEK inhibitors, this did not cause BIM up-
regulation (or apoptosis) to the extent seen with geﬁtinib.
Therefore, although MEK–ERK1/2 inhibition appears critical
for BIM dephosphorylation and accumulation, other signal-
ing pathways must contribute to achieve maximal BIM
induction and apoptosis. The identity of these pathways
remains to be determined.
Imatinib-induced transcriptional up-regulation of BIM in
BCR-ABL transformed cells was previously reported to be
mediated by FOXO3A [38] and linked to the shutdown of
PI3K–AKT signaling [39]. Because mutant EGFR potently
stimulates the AKT pathway [7], we anticipated that a similar
mechanism of BIM induction would be activated after
geﬁtinib treatment of NSCLC cells expressing hyperactive
mutant EGFR. However, although AKT phosphorylation was
abrogated as a component of the response to geﬁtinib
treatment, our data using pathway-speciﬁc inhibitors indicate
that PI3K–AKT may not be involved. As such, neither the
PI3K inhibitors LY294002 and Wortmannin nor a speciﬁc
AKT inhibitor had any effect on BIM induction in NSCLC
cells expressing mutant EGFR. This ﬁnding indicates that the
PI3K–AKT–FOXO3 pathway is not critical for BIM induction
after geﬁtinib treatment in these cells. However, this ﬁnding
does not preclude the possibility that PI3K–AKT inactivation
and consequent FOXO3A activation might play a role in the
apoptosis observed after geﬁtinib treatment, as these inhib-
itors all triggered apoptosis in NSCLC cells (unpublished
data). The downstream effectors of this apoptosis are
unknown but are likely to include the BH3-only proteins
BAD and PUMA, known targets of AKT [27] and FOXO3A
[40], respectively. With regard to LY294002, it is noteworthy
that this PI3K inhibitor did not substantially reduce AKT
phosphorylation in these NSCLC cells, but still evoked
apoptosis. Although surprising, this was a reproducible
ﬁnding (with two different sources of the inhibitor), which
Figure 5. Synergy between Gefitinib and ABT-737 in Killing of NSCLC
Cells Expressing Activating Mutations of EGFR
H358, H1650, H1975, and H3255 cells were treated with gefitinib (H358,
H1975, and H1650, 10 lM gefitinib; H3255, 1 lM gefitinib) in the presence
or absence of ABT-737 (1 lM) for 32 h (H3255 cells) or 48 h (H358, H1650,
H1975 cells). Cells were then harvested and survival measured as in Figure
1B. Data represent means 6 SEM of three experiments indicating
percentage of cell death compared to untreated cells.
doi:10.1371/journal.pmed.0040316.g005
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BIM in Gefitinib-Induced Apoptosisindicates the presence of a signaling pathway regulated by
PI3K but independent of AKT (and BIM). This pathway may
involve the above-mentioned FOXO3A-mediated induction
of the BH3-only protein PUMA [40].
A monoclonal antibody inhibitor of EGFR, cetuximab,
induced BIM in H3255 cells, although to a lesser extent and
with less dephosphorylation than that seen after treatment
with either geﬁtinib or erlotinib. This effect correlated with a
lower level of ERK1/2 dephosphorylation and less cell killing
elicited by cetuximab than that achieved by geﬁtinib (Figure
4F). In agreement with this observation, cetuximab was
previously shown to be less potent than geﬁtinib at inducing
apoptosis in other EGFR-mutant NSCLC cells [30]. Accord-
ingly, the combination of a MEK inhibitor with cetuximab
resulted in increased BIM induction, comparable to that
achieved by treatment with geﬁtinib, supporting the obser-
vation that MEK–ERK signaling is critical for BIM up-
regulation in these cells. This combination of cetuximab plus
MEK inhibitor also substantially enhanced apoptosis of the
H3255 cells compared to either agent alone, but not to the
level induced by geﬁtinib. This result supports the suggestion
that other MEK–ERK-independent signaling pathways (likely
those regulated by PI3K–AKT discussed above) also contrib-
ute to apoptosis induced by geﬁtinib in NSCLC harboring
activating mutations of EGFR. More generally, these data
reveal important differences between the signaling pathways
triggered by EGFR kinase inhibitors and those induced by
antagonistic monoclonal antibodies, and present a rational
means for improving clinical responses to cetuximab - by
combining it with MEK inhibitors.
Although initially promising it is now clear that EGFR
inhibitors such as geﬁtinib or erlotinib are unlikely to
provide cures in the majority of patients with NSCLC, even
in those with cancers expressing mutant EGFR. However,
understanding how these drugs work will provide critical
information to help design strategies to augment their
efﬁcacy. Here we have shown that BIM up-regulation is
essential for the apoptosis elicited by EGFR inhibitors in
NSCLC cells harboring EGFR activating mutations, and
detailed a number of the important mechanisms responsible.
The next step will be to ﬁnd strategies to augment the effects
of the EGFR-inhibitory drugs. For example, blockade of
signaling molecules within the Ras/MEK or PI3K/mTOR
pathways might augment the effects of EGFR therapeutics,
similar to their effects on chronic myelogenous leukemia cells
when used in conjunction with the BCR-ABL inhibitor
imatinib [41]. However, it should be noted that concurrent
treatment of H3255, HCC827, or H1650 cells with geﬁtinib
and a MEK inhibitor did not result in substantially enhanced
apoptosis (unpublished data), presumably because geﬁtinib
already efﬁciently inactivates ERK1/2 in these cells. There-
fore, drugs that target the PI3K/mTOR pathways may be more
successful.
Another therapeutic option is the use of BH3 mimetics, such
as ABT-737 [31]. Here we showed that ABT-737 substantially
enhanced geﬁtinib-induced apoptosis in all of the NSCLC cells
tested, albeit most prominently in those harboring the EGFR
activatingmutations.Thisactivityisreminiscentoftheabilityof
ABT-737 to increase imatinib-induced apoptosis of BCR-ABL
transformed cells [34]. We are currently assessing the efﬁcacy of
these combinations in suitable in vivo models in an attempt to
inform subsequent clinical trials.
In conclusion, our results demonstrate that BIM is essential
for geﬁtinib-induced killing of NSCLC cells expressing
mutant EGFR. Shutdown of the MEK–ERK1/2 pathway
appears critical for BIM up-regulation, but other signaling
pathways may also contribute. Finally, we have shown that
combining geﬁtinib with BH3 mimetics, such as ABT-737,
may be a potent strategy for enhancing the currently
suboptimal clinical responses seen in NSCLC.
Supporting Information
Figure S1. Mechanism of Apoptosis Induced in H3255 Cells after
Geﬁtinib Treatment
(A) H3255 NSCLC cells were left untreated (NT) or treated with 1 lM
geﬁtinib (Gef) or for 18 h. Cells were then harvested, lysed and
Western blotted for PARP.
(B and C) H3255 cells were left untreated or incubated for 30 min
with the caspase inhibitor QVD-OPH (25 lM) prior to the addition of
geﬁtinib, and cell samples were assessed for cell death at 16 h or 24 h
by Annexin V-FITC plus PI staining and ﬂow cytometric analysis.
Flow cytometry data from a representative experiment (B); mean 6
standard deviation of three independent experiments (C).
(D and E) H3255 cells were left untreated (NT) or incubated for 30
min with QVD-OPH prior to the addition of geﬁtinib (Gef, 1lM) and
cell samples assessed for BAX activation by ﬂow cytometry at 16 or 24
h (D) or by subcellular localization (E) at 18 h assessing membrane (M)
and cytosolic (C) compartments. Each fraction was assessed by
Western blotting for cytochrome c, BAX, BAK, and HSP70 (the latter
as a loading control).
Found at doi:10.1371/journal.pmed.0040316.sg001 (569 KB JPG).
Figure S2. BIM but not PUMA, BAX, or BAK Is Induced after
Geﬁtinib Treatment in H3225 Cells and Is Coincident with PARP
Cleavage
H3255 cells were treated with 1 lM geﬁtinib for 5–15 h and the cells
harvested, lysed and assessed by Western blotting for expression of
PARP, PUMA, BIM, BAK, BAX, and actin (loading control).
Found at doi:10.1371/journal.pmed.0040316.sg002 (156 KB JPG).
Figure S3. Kinetics of BIM Induction after Geﬁtinib Treatment in
HCC827 Cells
Bim is induced after geﬁtinib treatment in HCC827 cells and is
coincident with ERK dephosphorylation. HCC827 cells were treated
with 1 lM geﬁtinib for 2–28 h and the cells harvested, lysed and
assessed by Western blotting for expression of BIM, pERK, and actin
(loading control).
Found at doi:10.1371/journal.pmed.0040316.sg003 (119 KB JPG).
Figure S4. Effect of Geﬁtinib on NSCLC Cells
H358 and H441 cells expressing WT EGFR or H1975 cells expressing
L858R and T790M mutant EGFR were left untreated (NT) or treated
for 24 h with geﬁtinib (10, 2, 0.4, 0.08 lM) or DMSO (D). The cells
were then assessed by Western blotting for the phosphorylation status
of ERK1/2 and the level of BIM and actin (loading control).
Found at doi:10.1371/journal.pmed.0040316.sg004 (234 KB JPG).
Figure S5. BIM but Not PUMA mRNA Is Induced after Geﬁtinib
Treatment in NSCLC Cells Expressing Mutant EGFR
NSCLC cells were treated with 1 lM geﬁtinib for 2, 6, or 24 h (H3255)
or 24 h only (H1650). The cells were then harvested, total RNA
isolated and converted to cDNA. Semiquantitative PCR (A) or
quantitative PCR (B and C) analysis was then performed to determine
the levels of BIM or PUMA. Bars represent the mean 6 standard
deviation of three independent experiments.
Found at doi:10.1371/journal.pmed.0040316.sg005 (410 KB JPG).
Figure S6. Inhibition of EGFR Results in the Up-regulation and
Dephosphorlyation of BIM but Not BAD in H3225 Cells
H3255 cells were left untreated (NT) or were treated with inhibitors
of EGFR (1 lM geﬁtinib) for times ranging from 1 min to 16 h. The
cells were then harvested, lysed and assessed by Western blotting for
phosphorylated ERK1/2 (pERK1/2), BIM, phosphorylated BAD136,
phosphorylated BAD112, total BAD, PARP, BCL-xL, or actin (loading
control).
PLoS Medicine | www.plosmedicine.org October 2007 | Volume 4 | Issue 10 | e316 1688
BIM in Gefitinib-Induced Apoptosis(A) The rapid kinetics of pERK loss and coincident decrease in BIM
mobility on SDS-PAGE, indicative of dephosphorylation.
(B) The phosphorylation status of BAD and induction of BIMEL and
BIML over a 16 h time course. These data show that BAD136 but not
BAD112 is dephosphorylated after 16 h treatment with geﬁtinib,
coincident with PARP cleavage.
Found at doi:10.1371/journal.pmed.0040316.sg006 (379 KB JPG).
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BIM in Gefitinib-Induced ApoptosisEditors’ Summary
Background. Normally, cell division (which produces new cells) and cell
death are finely balanced to keep the human body in good working
order. But sometimes cells acquire changes (mutations) in their genetic
material that allow them to divide uncontrollably to form cancers—life-
threatening, disorganized masses of cells. One protein with a critical role
in cell division that is often mutated in tumors is the epidermal growth
factor receptor (EGFR). In normal cells, protein messengers bind to EGFR
and activate its tyrosine kinase. This enzyme then adds phosphate
groups to tyrosine (an amino acid) in proteins that form part of signaling
cascades (for example, the MEK–ERK signaling cascade) that tell the cell
to divide. In cancers that have mutations in EGFR, signaling is overactive
so the cancer cells divide much more than they should. Some non-small
cell lung cancers (NSCLC, the commonest type of lung cancer), for
example, have activating mutations within the EGFR tyrosine kinase.
Treatment with EGFR tyrosine kinase inhibitors (TKIs) such as gefitinib
and erlotinib induces the cells in these tumors to stop growing and die.
This cell death causes tumor shrinkage (regression) and increases the life
expectancy of patients with this type of NSCLC.
Why Was This Study Done? Unfortunately, treatment with TKIs rarely
cures NSCLC, so it would be useful to find a way to augment the effect
that TKIs have on cancer cells. To do this, the molecular mechanisms that
cause cancer-cell death and tumor regression in response to these drugs
need to be fully understood. In this study, the researchers have used a
combination of biochemical and genetic approaches to investigate how
gefitinib kills NSCLC cells with mutated EGFR.
What Did the Researchers Do and Find? The researchers first measured
the sensitivity of NSCLC cell lines (tumor cells that grow indefinitely in
dishes) to gefitinib-induced apoptosis. Gefitinib caused extensive
apoptosis in two cell lines expressing mutant EGFR but not in one
expressing normal EGFR. Next, they investigated the mechanism of
gefitinib-induced apoptosis in the most sensitive cell line (H3255).
Apoptosis is activated via two major pathways. Hallmarks of the
‘‘intrinsic’’ pathway include activation of a protein called BAX and
cytochrome c release from subcellular compartments known as
mitochondria. Gefitinib treatment induced both these events in H3255
cells. BAX (a proapoptotic member of the BCL-2 family of proteins) is
activated when proapoptotic BH3-only BCL-2 proteins (for example, BIM;
‘‘BH3-only’’ describes the structure of these proteins) bind to anti-
apoptotic BCL2 proteins. Gefitinib treatment rapidly increased BIM
activity in H3255 and HCC827 cells (but not in gefitinib-resistant cells) by
increasing the production of BIM protein and the removal of phosphate
groups from it, which increases BIM activity. Pharmacological blockade of
the MEK–ERK signaling cascade, but not of other EGFR signaling
cascades, also caused the accumulation of BIM. By contrast, blocking BIM
expression using a technique called RNA interference reduced gefitinib-
induced apoptosis. Finally, a combination of gefitinib and a BH3-
mimicking compound called ABT-737 (which, like BIM, binds to
antiapoptotic BCL-2 proteins) caused more apoptosis than gefitinib
alone.
What Do These Findings Mean? These findings (and those reported by
Gong et al. and Costa et al.) indicate that activation of the proapoptotic
BH3-only protein BIM is essential for gefitinib-induced killing of NSCLC
cells that carry EGFR tyrosine kinase mutations. They also show that
inhibition of the EGFR–MEK–ERK signaling cascade by gefitinib is
essential for BIM activation. Because these findings come from studies
on NSCLC cell lines, they need confirming in freshly isolated tumor cells
and in tumors growing in people. However, the demonstration that a
compound that mimics BH3 action enhances gefitinib-induced killing of
NSCLC cells suggests that combinations of TKIs and drugs that affect the
intrinsic pathway of apoptosis activation might provide a powerful
strategy for treating cancers in which tyrosine kinase mutations drive
tumor growth.
Additional Information. Please access these Web sites via the online
version of this summary at http://dx.doi.org/10.1371/journal.pmed.
0040316.
  A perspective by Ingo Mellinghoff discusses this article and two
related research articles
  Wikipedia pages on epidermal growth factor receptor, apoptosis, and
BCL2 proteins (note that Wikipedia is a free online encyclopedia that
anyone can edit; available in several languages)
  CancerQuest provides information on all aspects of cancer,/ext-link.
from Emory University (in several languages)
  US National Cancer Institute information for patients and professionals
on lung cancer (in English and Spanish)
  Information for patients from Cancer Research UK on lung cancer
including information on treatment with TKIs
  Information for patients from Cancerbackup on erlotinib and gefitinib
PLoS Medicine | www.plosmedicine.org October 2007 | Volume 4 | Issue 10 | e316 1690
BIM in Gefitinib-Induced Apoptosis